Summan' of the thesis Summary Vincristine, one of the naturally occurring vinca alkaloids extracted from the leaves of the periwinkle plant Catharanthus roseus. remains to be an important anti-neoplastic drug in paediatric oncology since its introduction in the early nineteen sixties. Vincristine is active against acute leukaemia, Hodgkin's and nonHodgkin's lymphoma, soft tissue sarcoma, Wilm's tumour, brain fumour and neuroblastoma. The dose-limiting side effect consists of a peripheral sensory, motor, and autonomic neuropathy. Other side effects, such as bone-marrow suppression, are relatively mild and no serious long-term side effects are known.
Summary
Vincristine, one of the naturally occurring vinca alkaloids extracted from the leaves of the periwinkle plant Catharanthus roseus. remains to be an important anti-neoplastic drug in paediatric oncology since its introduction in the early nineteen sixties. Vincristine is active against acute leukaemia, Hodgkin's and nonHodgkin's lymphoma, soft tissue sarcoma, Wilm's tumour, brain fumour and neuroblastoma. The dose-limiting side effect consists of a peripheral sensory, motor, and autonomic neuropathy. Other side effects, such as bone-marrow suppression, are relatively mild and no serious long-term side effects are known.
Because of its wide applicability and relatively mild bone-marrow suppression, vincristine is easy to combine with other anti-neoplastic drugs in a combination chemotherapy regimen. Therefore, it is worthwhile to try to optimize the treatment with vincristine in children.
Two goals can be distinguished when trying to optimize vincristine treatment: suppression of side effects and inrprovement of efficacy. The research presented in this thesis was focussed on improvement of vincristine efficacy. The antileukaemic effect of vincristine is principally determined by two factors: systemic exposure to vincristine and in vivo cell sensitivity to vincristine. First we hypothesized that the antileukaemic effect of vincristine might vary between patients as a consequence of interindividual variability in vincristine systemic exposure. If antileukaemic effect and systemic exposure are correlated, we could try to improve response by pharmacokinetically guided adaptation of the vincristine dose in each patient. The second part of the thesis was focussed on the mechanism of action of vincristine since better knowledge of its mechanism of action might help to understand differences in cell sensitivity to vincristine.
To place vincristine in a broad perspective of cancer chemotherapy in children, in chapter I we reviewed the current knowledge of pharmacokinetics and -dynamics of some anti-neoplastic drugs, used in the treatment of childhood t67 Summarv of the thesis cancer, and the experience with pharmacokinetically guided, individualized dosing.
Of all reviewed anti-neoplastic drugs, methotrexate appears to be most extensively studied. Methotrexate pharmacokinetics is correlated with toxicity and response to therapy, and individualtzed adaptive dosing of methotrexate is correlated with a better response to therapy, without increasing toxicity, in children with acute lymphoblastic leukaemia and osteosarcoma. For most of the other reviewed antineoplastic drugs, including vincristine, it is demonstrated that pharmacokinetics is correlated with toxicity. Of some drugs a relationship of pharmacokinetics with response to therapy is demonstrated as well. In case of cytarabine, etoposide, and teniposide, individualized dosing also appears to be feasible. However, there is no evidence that this strategy improves response to therapy. In children with acute lymphoblastic leukaemia and/or acute myeloid leukaemia, ct4arabine and teniposide adaptive dosing did not improve response. The effect of etoposide adaptive dosing on toxicity and response to therapy has not been studied up till now. Future research might answer the question whether this strategy improves etoposide response, and whether pharmacokinetics of carboplatin, ifosfamide, paclitaxel, and vincristine are correlated with response in children. There is a lack of knowledge on pharmacokinetic and -dynamic correlations in children for the anthracyclines, bleomycin, cispiatin, cyclophosphamide, and vinblastine. The research presented in this thesis, addresses the question whether pharmacokinetics of vincristine is correlated with response to vincristine monotherapy.
In the review. we also summarized existing knowledge from previous studies on vincristine pharmacokinetics and -dynamics. Vincristine is usually administered as an intravenous bolus dose and its disposition is described by a twocompartment, first-order model. Mean (SD) terminal elimination half-life and systemic clearance in children varied from 13.7 (6.5) to 18.7 (18.8) hours and 357 (146) to 482 (342) mlimin/m2 respectively, in different reports. In adult lung cancer patients, mean vincristine clearance was approximately 190 ml/min/ml. lntra-and 168 Summan: of the thesis interindividual variability of pharmacokinetic parameters in children appeared to be large.
Renal elimination of vincristine accounts for approximately l}Vo of systemic clearance in adults. Vincristine is predominantly excreted by the hepatobiliary pathway and a considerable amount of the parent drug is subject to hepatic metabolism before excretion into the bile. In line with the important role of hepatic clearance in vincristine elimination, increased serum alkaline phosphatase concentrations were associated with increased systemic exposure and elimination half-life of vincristine in a group of adult cancer patients, suggesting impaired hepatobiliary elimination. In several case reports severe vincristine toxicity was associated with co-administration of CYP3A4 inhibiting drugs during vincristine treatment and in some studies vincristine pharmacokinetics appeared to be affected by these drugs.
In each of the previous pharmacokinetic studies of vincristine in children, vincristine was administered in combination with other cytotoxic drugs or corticosteroids. Drug interactions may have contributed to the large interindividual variability that was detected in these studies. In chapter 2, we described the pharmacokinetics of vincristine as a monotherapy in a group of 70 children newly diagnosed with acute lymphoblastic leukaemia. Thus, these patients did not receive corticosteroids or other cytotoxic drugs during the period of the study. Vincristine Our second approach to improve vincristine efficacy was focussed on vincristine's mechanism of action, since an important step to better efficacy of a Summarv of the thesis drug is an improved knowledge of its mechanism of action. The antileukaemic effect of vincristine is traditionally attributed to inhibition of cell cycle progression due to interference with microtubule dynamics. However, it was also shown in vitro thaÍ vincristine induces apoptosis in leukaemic cell lines. Apoptosis is a process of cell death characterized by nuclear fragmentation with double-stranded DNA breaks, and cytoplasmic condensation and formation of apoptotic bodies, which can be removed by phagocy'tosis. The investigational up-front window study, described in this thesis, provided a unique opportunity to study vincristineinduced apoptosis in vivo in children with acute lymphoblastic leukaemia.
The results described in chapter 4, demonstrate that vincristine induces apoptosis ín vivo in peripheral blood mononuclear cells, mainly lymphoblasts, of children with acute lymphoblastic leukaemia. In five patients, participating in the investigational up-front window srudy of DCLSG protocol ALL-9, extra peripheral blood samples were collected on the first day of the study. The sampling was scheduled before and 3, 8, 12, 16, 20 , and 24 h after vincristine administration.
Peripheral blood mononuclear cells were isolated by density gradient centrifugation of the blood on Ficoll-Paque. The TTINEL (terminal deoxvnucleotide íransferase-mediated dUTP-digoxigenin nick-end labelling) assay was performed on 40Á paraformaldehyde-fixed cytospin slides of mononuclear cells to detect apoptosis. In one patient, a striking increase of apoptotic cells from 27o (SEM 0.6) before to 40.7oÁ (SEM 2.9) 3 h after vincristine injection was found. In the other patients the maximum increase ranged from 0.8%o to 4.3oÁ. Wilcoxon matched pairs analysis of all patients confirmed that vincristine induces apoptosis in vivo in peripheral blood mononuclear cells in children with acute lymphoblastic leukaemia.
In chapter 5 we further studied the route of vincristine-induced apoptosis. In the process of apoptosis caspases play a critical role. Caspases are cysteine proteases that exist as proenzymes and are activated upon cleavage. In cell-free extracts activation occurs in a hierarchical order. Evidence is accumulating that the caspase cascades differ depending on the apoptotic stimulus. In apoptosis induced by CD95-receptor signalling, caspase-8 is the most proximal caspase, activated by autoproteolysis after recruitment to the intracellular located adaptor proteins FADD of the CD95-receptor complex. In apoptosis induced by apoptotic stimuli that activate the mitochondrial controlled pathway, the most proximal caspase is caspase-9, which can be activated after cytochrome C and dATP-dependent formation of a caspase-9lApaf-| complex. It is shown that mitochondrial changes such as cy'tochrome C release, loss of mitochondrial membrane potential and the production of reactive oxygen species. can precede caspase-9 activation during apoptosis. Furthermore, it is known that the pro-and anti-apoptotic members of the Bax/Bcl-2 protein family regulate mitochondrial cyochrome C release and apoptosis. Apoptosis induced by several DNA-damaging anti-neoplastic drugs does not require CD95-receptor signalling but most often follows a CD95-independent, mitochondrial controlled pathway. It is unclear whether apoptosis induced by vincristine proceeds by a mitochondrial controlled pathway.
The results presented in chapter 5 demonstrate caspase-9 and -3 activation ir vivo in bone marrow leukaemic cells of a child with newly diagnosed acute lymphoblastic leukaemia, after treatment with a single dose of vincristine. We hypothesized that vincristine induces apoptosis by a mitochondrial controlled pathway and we further studied its mechanism of action in Jurkat acute lymphoblastic leukaemia cells. Vincristine-induced activation of caspase-9 and subsequently caspase-3 was demonstrated by western blot analysis of cell lysates, cell lineages in the ability to eliminate reactive oxygen species might be responsible for differences in cell sensitivity to vincristine.
